Neuropace Inc (NPCE) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neuropace Inc   (NASDAQ: NPCE)


Neuropace Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Neuropace Inc's ROI in the second quarter of 2026?
Neuropace Inc recorded a cumulative net loss of $-19 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -22.64%.

Within the Healthcare sector 322 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2570 to 3411.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -2.26 % 2.6 % 9.53 % 6.51 % 3.11 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 80 83 88 88 89
Return On Investment (TTM) -22.64 % -24.85 % -23.86 % -27.29 % -30.04 %
NPCE's Overall Ranking # 3411 # 2570 # 2474 # 3032 # 3096
Seq. Investment Change TTM -2.71 % -3.55 % 2.35 % 1.77 % 2.12 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -19 -22 -21 -24 -26

NPCE Company Profile >> Back to NPCE Roi Comparisons >> See Annual NPCE Return On Investment



Return On Investment NPCE's Ranking
Within: No.
Industry # 101
Sector # 323
Overall # 3411

Return On Investment Statistics
High Average Low
-22.64 %
-36.65 %
-89.18 %
(Jun 30 2026)   (Mar 31 2021)



  News about Neuropace Inc Return on Investment ROI

NeuroPace Reports Promising Revenue Growth for Q4 2023 and Full Year 2023, Despite Recent Financial Setbacks

January 8, 2024


NeuroPace, a leading medical technology company specializing in neuromodulation therapies, announced its preliminary unaudited revenue for the fourth quarter and full year 2023, along with some important business updates. The company expects its revenue for Q4 2023 to fall between $17.5 million and $18.0 million, while the full-year revenue is projected to be in the range of $64.9 million and $65.4 million. These figures indicate a steady growth for NeuroPace, despite some recent financial challenges.
During the 12 months leading up to the third quarter of 2023, NeuroPace Inc recorded a cumulative net loss of $-38 million, resulting in a negative return on investment (ROI) of -40.24%. This news comes as a setback for the company, which aims to bring innovative neuromodulation therapies to patients suffering from neurological disorders such as epilepsy.





Financial Statements
Neuropace Inc's II. Quarter Investments $ 80 Millions NPCE's Balance sheet
Neuropace Inc's II. Quarter Income $ -6 Millions Quarterly NPCE's Income Statement
NPCE's Income by Division See NPCE's Income by Division


NPCE Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 88 79 81 103 124
Y / Y Investment Growth 10.39 % -1.92 % -21.42 % -17.01 % -
Net Income in Millions -21 -27 -33 -47 -36
Y / Y Net Income Growth - - - - -
Annual Return On Investment -24.46 % -34.14 % -40.66 % -45.65 % -29.04 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NPCE's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NPCE's Competitors
Subscribers only: Roi for Neuropace Inc's Suppliers
Subscribers only: Return On Investment for NPCE's Customers

Other Ratios
NPCE's Roa NPCE's Inventory Turnover Ratio NPCE's Growth Rates NPCE's Dividend Statistics
NPCE's Profitability Ratios NPCE's Asset Turnover Ratio NPCE's Dividend Growth
NPCE's Roe NPCE's Valuation Ratios NPCE's Financial Strength Ratios NPCE's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:39:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.